Analytical Data
-
Gene name
BDKRB1
- Application
-
Alternative Names
BDKRB1; BRADYB1; B1 bradykinin receptor; B1R; BK-1 receptor
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P46663
-
Expression Region
1-353aa
-
AA Sequence
MASSWPPLELQSSNQSQLFPQNATACDNAPEAWDLLHRVLPTFIISICFFGLLGNLFVLLVFLLPRRQLNVAEIYLANLAASDLVFVLGLPFWAENIWNQFNWPFGALLCRVINGVIKANLFISIFLVVAISQDRYRVLVHPMASRRQQRRRQARVTCVLIWVVGGLLSIPTFLLRSIQAVPDLNITACILLLPHEAWHFARIVELNILGFLLPLAAIVFFNYHILASLRTREEVSRTRCGGRKDSKTTALILTLVVAFLVCWAPYHFFAFLEFLFQVQAVRGCFWEDFIDLGLQLANFFAFTNSSLNPVIYVFVGRLFRTKVWELYKQCTPKSLAPISSSHRKEIFQLFWRN
-
Molecular Weight
40.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BDKRB1, or bradykinin B1 receptor, is a G protein-coupled receptor that plays a significant role in various physiological processes, including inflammation, pain modulation, and cardiovascular regulation. Unlike the bradykinin B2 receptor, which is constitutively expressed and plays a role in normal physiological responses, BDKRB1 is primarily upregulated in response to inflammatory stimuli and has been implicated in chronic pain and inflammatory diseases. The reactivation of this receptor in pathological conditions highlights its potential as a therapeutic target. Research into the recombinant expression of BDKRB1 protein is crucial for understanding its structural and functional properties, enabling the development of specific inhibitors or modulators that can offer new treatment avenues for conditions linked to excessive inflammation and pain. By producing BDKRB1 in a recombinant system, researchers can better analyze its binding characteristics and downstream signaling pathways, facilitating the identification of novel drug candidates. Additionally, the study of BDKRB1 recombinant protein can provide insights into receptor-ligand interactions and contribute to the development of targeted therapies, making it a significant focus in pharmacology and biomedical research.
